---
layout: post
title: "Determination of Regulatory Review Period for Purposes of Patent Extension; ENHERTU; Correction"
date: 2026-02-05 18:57:41 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-00404
original_published: 2022-01-12 00:00:00 +0000
significance: 8.00
---

# Determination of Regulatory Review Period for Purposes of Patent Extension; ENHERTU; Correction

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** January 12, 2022 00:00 UTC
**Document Number:** 2022-00404

## Summary

The Food and Drug Administration (FDA or the Agency) published a notice in the Federal Register of November 1, 2021, for the determination of a regulatory review period for purposes of patent extension for the human biological product, ENHERTU. This document corrects that notice by adjusting the applicable regulatory review period for the testing phase and approval phase of the product, ENHERTU.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/01/12/2022-00404/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enhertu-correction)
- API: https://www.federalregister.gov/api/v1/documents/2022-00404

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
